title: The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials.
abstract: Basic research in solid malignant tumours has led to a wealth of knowledge about this disease process and about novel ways to more effectively target our therapies. Laboratory research continues to identify novel therapeutic targets and moreover, clinical research is identifying effective new treatment regimens. Many preclinical studies in this area have targeted the epidermal growth factor receptor (EGFR) signalling pathway to increase radiosensitivity. The in vitro rationale for targeting EGFR and concurrent ionising radiation is well established, but to date, rare clinical data could provide proof-of-principle. Here we report all the different published clinical trials focusing on efficacy and toxicity in order to clarify and to summarise the present state-of-the-art of this particularly promising combination in solid tumour management.
authors.affiliation: Department of Radiotherapy, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94 805 Villejuif, France. nicolas.magne@igr.fr
authors.forename: Nicolas
authors.initials: N
authors.lastname: Magné
authors.forename: Cyrus
authors.initials: C
authors.lastname: Chargari
authors.forename: Pierre
authors.initials: P
authors.lastname: Castadot
authors.forename: Mithra
authors.initials: M
authors.lastname: Ghalibafian
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Soria
authors.forename: Christine
authors.initials: C
authors.lastname: Haie-Meder
authors.forename: Jean
authors.initials: J
authors.lastname: Bourhis
authors.forename: Eric
authors.initials: E
authors.lastname: Deutsch
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068818:Cetuximab; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D000068818:Cetuximab; D000077156:Gefitinib